Kura Oncology, Inc.
NASDAQ: KURA0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- NASDAQ
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Troy Wilson
- Employees
- 260
- Headquarters
- San Diego, United States
- IPO year
- 2015
- Market cap
- $942.8M
- Website
- https://kuraoncology.com
Loading KURA…
Loading profile data…Frequently asked questions about KURA
What does Kura Oncology, Inc. (KURA) do?
Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company’s first commercial product, KOMZIFTI (ziftomenib), a potent, selective, reversible and oral small molecule menin inhibitor; Darlifarnib, a Phase 1 first-in-human FIT-001 trial which includes multiple cohorts to evaluate da...
Where does KURA trade?
Kura Oncology, Inc. (KURA) trades on the NASDAQ.
What sector is KURA in?
Kura Oncology, Inc. (KURA) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Kura Oncology, Inc.?
Troy Wilson is the chief executive officer of Kura Oncology, Inc. (KURA).
Where is Kura Oncology, Inc. headquartered?
Kura Oncology, Inc. is headquartered in United States.
Does KURA pay a dividend?
Kura Oncology, Inc. (KURA) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did KURA go public?
Kura Oncology, Inc. (KURA) completed its initial public offering in 2015.